Table 3.

Any change in tumour markers and inflammatory indices and changes according to cut-off values

204 RECIST
204 CEA	130 CA19-9	116 NLR, PLR, LMR and SII
PD 31%	PD/DC	DC 69%
CEA: 82%↑; 18%↓	↔a	CEA: 28%↑; 72%↓
↕c		↕c
∆CEA (24.52%): 80.3%↑; 19.7%↓	↔a	∆CEA (24.52%): 19.6%↑; 80.4%↓
CA19-9: 75.6%↑ ; 24.4%↓	↔a	CA19-9: 33.7%↑; 66.3%↓
↕c		↕c
∆CA19-9 (21.49%): 73.2%↑; 26.8%↓	↔a	∆CA19-9 (21.49%): 30.3%↑; 69.7%↓
NLR: 45%↑; 55%↓	↔c	NLR: 54.2↑; 45.8%↓
↕c		↕b
∆NLR (11.05%): 66.7%↑; 33.3%↓	↔a	∆NLR (11.05%): 33.7%↑ 66.3%↓
PLR: 55%↑; 45%↓	↔c	PLR: 44.8%↑; 55.2%↓
↕c		↕c
∆PLR (5.90%): 52.8%↑; 47.2%↓	↔b	∆PLR (5.90%): 32.5%↑; 67.5%↓
LMR: 45%↑; 55%↓	↔c	LMR: 41.7%↑; 58.3%↓
SII: 30%↑; 70%↓	↔c	SII: 42.7%↑; 57.3%↓
↕a		↕c
∆SII (-6.04%): 72.2%↑; 27.8%↓	↔a	∆SII (-6.04%): 33.7%↑; 66.3%↓

^a P > 0.01.

^b P < 0.05.

^c P > 0.05.

Carcinoembryonic antigen, carbohydrate antigen, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio (LMR) and systemic immune-inflammation index any increase or decrease of value; ∆- increase or decrease defined by cut-off obtained with receiver operating characteristic analysis; ↕ and ↔ statistical analysis with χ² test; ∆LMR cut-off was not determined. PD: Progressive disease; DC: Disease control; SD: Stable disease (CR + PR + SD); CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; LMR: Lymphocyte-to-monocyte ratio; SII: Systemic immune-inflammation index.